Search Bar & Filters
Found 216 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of elenestinib BLU-263 combined with symptom directed therapy SDT compared to placebo plus SDT in adults with indolent systemic mastocytosis ISM whose symptoms are not well controlled by SDT alone. This Phase 23 randomized, double-blind, placebo-controlled study includes participants from Parts 1 and 2 with ISM, with those in Part 2 continuing into Part 3 for open-label elenestinib treatment. Part K enrolls participants with prior use of selective KIT inhibitors, and additional pharmacokinetic groups will also participate. Participants receive SDT tailored individually and take either oral elenestinib or matching placebo once daily. In Part 1, treatment continues until study completion, while Part 2 involves approximately 48 weeks of dosing. Part 3 and other parts may extend treatment up to about 5 years. The study monitors participants throughout these periods, with dosing and symptom management adjusted as needed. During the study, participants undergo various assessments including symptom scoring with the Indolent Systemic Mastocytosis-Symptom Assessment Form ISM-SAF, safety monitoring for adverse events, and laboratory tests such as serum tryptase levels and KIT D816V allele fraction. Bone marrow mast cells, bone mineral density, and quality of life measures are also evaluated. Researchers track these outcomes at multiple timepoints from baseline up to 5 years to understand treatment impact and participant safety.
Actively Recruiting
Researchers are investigating new treatments for advanced renal cell carcinoma RCC, a type of kidney cancer. This study compares a standard targeted therapy called belzutifan with a combination of belzutifan and another targeted therapy, zanzalintinib. The goal is to find out if adding zanzalintinib helps people with advanced RCC live longer and without their cancer worsening compared to belzutifan alone. Participants will be randomly assigned to one of two groups. One group will take 120 mg of belzutifan orally plus 60 mg of zanzalintinib once daily for about 24 months. The other group will take 120 mg of belzutifan plus a placebo matching zanzalintinib once daily for the same period. Both treatments are given as tablets taken by mouth. During the study, participants will have regular evaluations to monitor their cancers status, side effects, and quality of life. Researchers will use specific measures such as progression-free survival PFS and overall survival OS over up to 50 months. Other assessments include tumor response, duration of response, adverse events, and changes in health questionnaires related to physical function and symptoms. Safety and treatment effects will be carefully tracked throughout the study.
Actively Recruiting
Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.
Actively Recruiting
Researchers are evaluating the effects of an investigational medicine called PGN-EDODM1 to understand how safe and tolerable multiple doses are for adults with myotonic dystrophy type 1 DM1. This phase 2 study compares PGN-EDODM1 to a placebo to assess its safety and tolerability in people with this condition. Participants will be randomly assigned to receive either PGN-EDODM1 or a placebo. The treatment is given by intravenous infusion once every 4 weeks for a total of 12 weeks. Those in the PGN-EDODM1 group will receive ascending doses, while the placebo group will receive saline infusions on the same schedule. During the study, participants will be monitored for safety by tracking adverse events from the start through Day 112. Researchers will measure drug levels in the blood, changes in muscle tissue, myotonia severity, hand grip strength, and mobility using specific tests. The total participation lasts through about 16 weeks, including treatment and follow-up assessments.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and how the body processes a medication called NXT007 compared with another treatment called emicizumab for people aged 12 years and older who have severe or moderate congenital hemophilia A without inhibitors or any severity of hemophilia A with inhibitors. The study is a Phase III clinical trial focused on treatment to understand these two prophylaxis options better. Participants are randomly assigned to receive either NXT007 or emicizumab prophylaxis during the main treatment period. Emicizumab is given with a loading dose of 3 mgkg weekly for 4 weeks, followed by maintenance doses at different intervals, while NXT007 is administered subcutaneously as an integrated drug-device product. After the main treatment period, participants on NXT007 can continue this treatment, and those on emicizumab can switch to NXT007 during an open-label extension phase. During the study, participants will be monitored for bleeding rates, treatment burden, and safety through various assessments including questionnaires and blood tests. Researchers will track adverse events, immune responses to NXT007, and drug levels over approximately 3.5 years. The primary measure is the annualized rate of treated bleeds from month 2 onward, with study completion expected in 2032.
Actively Recruiting
Researchers are evaluating NXT007 prophylaxis compared with Factor VIII FVIII prophylaxis in people aged 12 years and older who have severe or moderate congenital hemophilia A without FVIII inhibitors. The study aims to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 in preventing bleeds compared to the standard FVIII treatment. Participants must have been on FVIII prophylaxis before joining the trial. Participants will be randomly assigned to receive either NXT007 prophylaxis or FVIII standard of care prophylaxis during the main study treatment period lasting six months. NXT007 is given by subcutaneous injection using a drug-device combination product, while FVIII is administered according to local dosing guidelines. After this period, those on NXT007 may continue its dosing, and those originally on FVIII can switch to NXT007 in an open-label extension phase. During the study, participants will be monitored regularly for bleeding rates, treatment burden, and quality of life using questionnaires like CATCH and TASQ. Safety will be assessed through adverse event monitoring, including injection-site reactions and thromboembolic events. Blood samples will be collected to measure NXT007 levels and immune response over approximately 3.5 years. The main outcome measured is the annualized bleed rate for treated bleeds over six months.
Actively Recruiting
Researchers are evaluating the safety, optimal dose, and effectiveness of a combination treatment involving BNT323 trastuzumab pamirtecan and BNT327 pumitamig in people with advanced breast cancer. This includes patients with hormone receptor-positive or negative, HER2-positive, HER2-low, HER2-ultralow, HER2-null breast cancer, or triple-negative breast cancer. The study is a Phase III, multi-site, open-label trial designed to find the best dose and assess the treatments effects in these groups. The study has two parts. Part 1 involves dose escalation where participants with chemotherapy-pretreated advanced breast cancer receive various dose levels of BNT323 plus BNT327 to determine the recommended Phase 2 dose. Part 2 includes dose optimization and exploratory groups, beginning after Part 1s completion. In Part 2 Cohort 1, participants are randomized into four arms to receive either the combination at the recommended dose, the combination at another dose, BNT323 alone, or BNT327 alone. Other cohorts receive the recommended dose without randomization. Participants will undergo treatment cycles with intravenous infusions of the study drugs and be monitored for safety, side effects, and tumor response for up to 36 months. Assessments include tracking dose-limiting toxicities, adverse events, tumor scans, and response rates. Safety monitoring continues up to 90 days after the last dose. The study aims to provide detailed information on the best dose, safety, and potential benefits of these treatments for advanced breast cancer.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, best dose, and how the body processes a drug called BNT326 alone and combined with other immunotherapies in people with advanced solid tumors. These tumors are either metastatic, recurrent, or have progressed despite prior treatments. The study includes multiple specific tumor types and is divided into two parts, each enrolling participants independently to assess BNT326 alone or with other drugs like pumitamig. Participants in Part 1 receive BNT326 alone in different groups based on their tumor type, including cutaneous melanoma, non-small cell lung cancer, rare melanomas, cervical cancer, and other solid tumors. Part 2 studies BNT326 alone or combined with pumitamig for various cancers such as melanoma, breast cancer, gastric cancer, colorectal cancer, and cervical cancer. Some groups involve random assignment to different dose levels, while others do not. Treatments are given via intravenous infusion or oral administration depending on the drug. Participants undergo a screening period followed by treatment lasting up to 24 months or until disease progression, consent withdrawal, study end, or unacceptable side effects. After treatment, there are safety and efficacy follow-up periods, plus long-term survival tracking, with total involvement lasting about 38 months for Part 1 and 48 months for Part 2. Researchers monitor side effects, tumor response, survival, and drug levels in the blood to assess safety and activity of the treatments.
Actively Recruiting
Researchers are evaluating new treatment options for people with locally advanced, unresected non-small cell lung cancer NSCLC that has a KRAS G12C gene mutation. This trial aims to learn if combining calderasib MK-1084 with durvalumab, an immunotherapy, after chemotherapy and radiation can help patients live longer without their cancer growing or spreading. Participants will be randomly assigned to receive either calderasib along with durvalumab or a placebo with durvalumab. Calderasib is taken as an oral tablet, while durvalumab is given by intravenous infusion. The study is blinded so neither participants nor researchers know who receives the active drug or placebo during treatment. During the study, participants will be monitored regularly to assess cancer progression, survival, quality of life, and side effects. This includes tumor testing, blood work, and questionnaires over up to approximately 6 years for progression-free survival and up to 9 years for overall survival and other health measures. The study is sponsored by Merck Sharp & Dohme LLC and follows participants from screening through long-term follow-up.
Actively Recruiting
Researchers are conducting a first-in-human, multi-center trial to study the effects of SRP-1005 in adults diagnosed with Huntingtons disease HD. This phase 1 study aims to evaluate the treatments safety and how the body processes SRP-1005, a drug administered by subcutaneous injection. The trial involves participants at specific stages of HD to better understand the impact of this investigational medication. Participants are randomly assigned to one of four groups receiving different doses of SRP-1005 or a placebo. All treatments are given by subcutaneous injection, with the study designed to carefully monitor each dose level. This randomized, double-blind, placebo-controlled trial includes dose escalation to assess safety and the drugs behavior at various concentrations. During the study, participants will undergo regular assessments to monitor adverse events and measure SRP-1005 levels in plasma, urine, and cerebrospinal fluid. The trial includes lumbar punctures and MRI scans as part of safety and feasibility evaluations. The main focus is on tracking any treatment-related side effects through week 24, with additional monitoring of drug concentration up to day 17 and cerebrospinal fluid levels through week 24. Participants are expected to be involved for about six months, including safety follow-up.
1-10 of 216
1